JP2024529975A5 - - Google Patents

Info

Publication number
JP2024529975A5
JP2024529975A5 JP2024505286A JP2024505286A JP2024529975A5 JP 2024529975 A5 JP2024529975 A5 JP 2024529975A5 JP 2024505286 A JP2024505286 A JP 2024505286A JP 2024505286 A JP2024505286 A JP 2024505286A JP 2024529975 A5 JP2024529975 A5 JP 2024529975A5
Authority
JP
Japan
Prior art keywords
protein
sequence
rna molecule
composition
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529975A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074337 external-priority patent/WO2023010128A2/en
Publication of JP2024529975A publication Critical patent/JP2024529975A/ja
Publication of JP2024529975A5 publication Critical patent/JP2024529975A5/ja
Pending legal-status Critical Current

Links

JP2024505286A 2021-07-30 2022-07-29 Rnaワクチン Pending JP2024529975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227972P 2021-07-30 2021-07-30
US63/227,972 2021-07-30
PCT/US2022/074337 WO2023010128A2 (en) 2021-07-30 2022-07-29 Rna vaccines

Publications (2)

Publication Number Publication Date
JP2024529975A JP2024529975A (ja) 2024-08-14
JP2024529975A5 true JP2024529975A5 (cg-RX-API-DMAC7.html) 2025-08-05

Family

ID=85088269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505286A Pending JP2024529975A (ja) 2021-07-30 2022-07-29 Rnaワクチン

Country Status (14)

Country Link
US (1) US20230219996A1 (cg-RX-API-DMAC7.html)
EP (1) EP4376883A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024529975A (cg-RX-API-DMAC7.html)
KR (1) KR20240050353A (cg-RX-API-DMAC7.html)
CN (1) CN118043068A (cg-RX-API-DMAC7.html)
AR (1) AR126625A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022319940A1 (cg-RX-API-DMAC7.html)
BR (1) BR112024001911A2 (cg-RX-API-DMAC7.html)
CA (1) CA3226806A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240095A (cg-RX-API-DMAC7.html)
IL (1) IL310107A (cg-RX-API-DMAC7.html)
MX (1) MX2024001464A (cg-RX-API-DMAC7.html)
TW (1) TW202313967A (cg-RX-API-DMAC7.html)
WO (1) WO2023010128A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
WO2024211625A1 (en) * 2023-04-07 2024-10-10 Arcturus Therapeutics, Inc. Hbv gene editing
WO2025103414A1 (zh) * 2023-11-14 2025-05-22 上海瑞宏迪医药有限公司 一种脂质纳米粒的制备方法和应用
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025161942A1 (zh) * 2024-02-02 2025-08-07 仁景(苏州)生物科技有限公司 用于递送的脂质化合物和脂质纳米颗粒
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2026029847A1 (en) * 2024-07-29 2026-02-05 Arcturus Therapeutics, Inc. Methods and compositions for pandemic influenza vaccine
CN121021427A (zh) * 2024-07-30 2025-11-28 广州市恒诺康医药科技有限公司 可离子化脂质及其用途
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)
JP7657411B1 (ja) * 2025-01-23 2025-04-07 医療法人すぎやま内科 乳がん細胞の増殖抑制剤及び乳がん治療剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2922554T (pt) * 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
KR20180074699A (ko) * 2015-11-09 2018-07-03 이뮨 디자인 코포레이션 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
JP7788787B2 (ja) * 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 遺伝子発現増強のための組成物および方法
US11802146B2 (en) * 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
EP3864027A1 (en) * 2018-10-08 2021-08-18 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
US11406699B2 (en) * 2019-03-22 2022-08-09 George Mason University Alphavirus and compositions, methods, and kits related thereto
WO2020209929A1 (en) * 2019-04-09 2020-10-15 Massachusetts Institute Of Technology Mutant subgenomic promoter library and uses thereof
EP3986452A1 (en) * 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
EP3986458A1 (en) * 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
EP4061405A1 (en) * 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
WO2022043551A2 (en) * 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines

Similar Documents

Publication Publication Date Title
JP2023517644A5 (cg-RX-API-DMAC7.html)
US12350330B2 (en) RSV RNA molecules and compositions for vaccination
Fang et al. Advances in COVID-19 mRNA vaccine development
US20240398940A1 (en) Novel lipid nanoparticles for delivery of nucleic acids
ES2968649T3 (es) Nanopartículas lipídicas para la administración de ARNm en los pulmones
US20230219996A1 (en) Rna vaccines
CA3171219A1 (en) Compositions and methods for inducing immune responses
US20220062409A1 (en) Heterologous prime boost vaccine compositions and methods
JP2021105023A (ja) 切断可能な脂質
JP2024534900A (ja) ホスファチジルセリンを含む核酸を送達するための新規な脂質ナノ粒子
US20220016237A1 (en) Rna replicon vaccines against hbv
CA3215112A1 (en) Compositions and methods for delivery of rna
US20200215157A1 (en) Composition and methods for treatment of primary ciliary dyskinesia
US20220054611A1 (en) Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer
JP2026503735A (ja) 四価インフルエンザワクチンのための方法及び組成物
JP2026509258A (ja) 核酸送達のための新規な脂質ナノ粒子製剤
CN117940118A (zh) 用于核酸递送的新型脂质纳米颗粒
WO2024152996A1 (zh) 自复制信使核糖核酸疫苗
WO2026029847A1 (en) Methods and compositions for pandemic influenza vaccine
HK40110708A (en) Rna vaccines
WO2025265034A1 (en) Transitory modulation of gene transcription through targeted mrna-lnp delivery of modified transcription activator-like effectors (tale)
CN117440824A (zh) 抗SARS-CoV-2变体的RNA疫苗
JP2025507234A (ja) 自己複製rna及びその使用配列表 本出願は、電子形態の配列表とともに出願される。配列表の全内容は、参照によって本明細書に組み込まれる。
CN118119404A (zh) 免疫原性lnp组合物及其方法
HK40091626A (en) Rna replicon vaccines against hbv